Fig. 4: Plasma concentration-time profile of ABBV-467 in patients with MM. | Communications Medicine

Fig. 4: Plasma concentration-time profile of ABBV-467 in patients with MM.

From: Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients

Fig. 4

Plasma concentration-time profile of half or target dose of ABBV-467 on a linear or log scale. Plasma concentrations were undetectable at time points sampled after 4 h. Open circles are from individual patient concentrations and solid circles represent mean plasma concentrations at the corresponding timepoint. Patients with undetectable or zero concentration values are not displayed on the logarithmic scale. RStudio (Version 1.4) was used to assist in data presentation. MM, multiple myeloma.

Back to article page